These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 23433901)

  • 1. The additional diagnostic value of contemporary evaluation of FDG PET/CT scan and contrast enhanced CT imaging both acquired by a last generation PET/CT system in oncologic patients.
    Nanni C; Zompatori M; Ambrosini V; Montesi V; Mezzetti S; Ferretti A; Chondrogiannis S; Rubello D; Fanti S
    Biomed Pharmacother; 2013 Mar; 67(2):172-8. PubMed ID: 23433901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Performance of FDG PET/ceCT in the evaluation of patients with lung cancer.
    Nanni C; Rossetti V; Zompatori M; Ambrosini V; Montesi V; Mascherini D; Pettinato C; Marzola MC; Colletti PM; Rubello D; Fanti S
    Biomed Pharmacother; 2014 Mar; 68(2):219-23. PubMed ID: 24486108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Value of FDG PET/Contrast-Enhanced CT in Initial Staging of Colorectal Cancer - Comparison with Contrast-Enhanced CT.
    Kunawudhi A; Sereeborwornthanasak K; Promteangtrong C; Siripongpreeda B; Vanprom S; Chotipanich C
    Asian Pac J Cancer Prev; 2016; 17(8):4071-5. PubMed ID: 27644663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can full-dose contrast-enhanced CT be omitted from an FDG-PET/CT staging examination in newly diagnosed FDG-avid lymphoma?
    van Hamersvelt HP; Kwee TC; Fijnheer R; Beek FJ; de Klerk JM; Nievelstein RA
    J Comput Assist Tomogr; 2014; 38(4):620-5. PubMed ID: 24681861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ¹⁸F-FDG PET/contrast enhanced CT in the standard surveillance of high risk colorectal cancer patients.
    Jiménez Londoño GA; García Vicente AM; Sánchez Pérez V; Jiménez Aragón F; León Martin A; Cano Cano JM; Domínguez Ferreras E; Gómez López OV; Espinosa Arranz J; Soriano Castrejón ÁM
    Eur J Radiol; 2014 Dec; 83(12):2224-2230. PubMed ID: 25306106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle.
    Mertens LS; Fioole-Bruining A; Vegt E; Vogel WV; van Rhijn BW; Horenblas S
    BJU Int; 2013 Oct; 112(6):729-34. PubMed ID: 23790129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FDG PET and Split-Bolus Multi-Detector Row CT Fusion Imaging in Oncologic Patients: Preliminary Results.
    Scialpi M; Palumbo I; Gravante S; Buresta T; D'Andrea A; Pierotti L; Palumbo B
    Radiology; 2016 Mar; 278(3):873-80. PubMed ID: 26361222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of intravenous contrast in PET/CT: does it really introduce significant attenuation correction error?
    Yau YY; Chan WS; Tam YM; Vernon P; Wong S; Coel M; Chu SK
    J Nucl Med; 2005 Feb; 46(2):283-91. PubMed ID: 15695788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contrast-enhanced PET/MR imaging versus contrast-enhanced PET/CT in head and neck cancer: how much MR information is needed?
    Kuhn FP; Hüllner M; Mader CE; Kastrinidis N; Huber GF; von Schulthess GK; Kollias S; Veit-Haibach P
    J Nucl Med; 2014 Apr; 55(4):551-8. PubMed ID: 24491410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Value of fusion of PET and MRI for staging of endometrial cancer: comparison with ¹⁸F-FDG contrast-enhanced PET/CT and dynamic contrast-enhanced pelvic MRI.
    Kitajima K; Suenaga Y; Ueno Y; Kanda T; Maeda T; Takahashi S; Ebina Y; Miyahara Y; Yamada H; Sugimura K
    Eur J Radiol; 2013 Oct; 82(10):1672-6. PubMed ID: 23727380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utility of (18)F-FDG PET-CT in staging and restaging of patients with malignant salivary gland tumours: a single-institutional experience.
    Sharma P; Jain TK; Singh H; Suman SK; Faizi NA; Kumar R; Bal C; Malhotra A; Kumar R
    Nucl Med Commun; 2013 Mar; 34(3):211-9. PubMed ID: 23353886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective evaluation of CECT and 18F-FDG-PET/CT in detection of hepatic metastases.
    D'souza MM; Sharma R; Mondal A; Jaimini A; Tripathi M; Saw SK; Singh D; Mishra A; Tripathi RP
    Nucl Med Commun; 2009 Feb; 30(2):117-25. PubMed ID: 19057427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Staging pathways in recurrent colorectal carcinoma: is contrast-enhanced 18F-FDG PET/CT the diagnostic tool of choice?
    Soyka JD; Veit-Haibach P; Strobel K; Breitenstein S; Tschopp A; Mende KA; Lago MP; Hany TF
    J Nucl Med; 2008 Mar; 49(3):354-61. PubMed ID: 18287263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum carcinoembryonic antigen measurement, abdominal contrast-enhanced computed tomography, and fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in the detection of colorectal cancer recurrence: a correlative study.
    Ozkan E; Soydal C; Araz M; Aras G
    Nucl Med Commun; 2012 Sep; 33(9):990-4. PubMed ID: 22842225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic Contribution of Contrast-Enhanced CT as Compared with Unenhanced Low-Dose CT in PET/CT Staging and Treatment Response Assessment of
    Marchetti L; Perrucci L; Pellegrino F; Baroni L; Merlo A; Tilli M; Rambaldi I; Maietti E; Carnevale A; Bartolomei M; Giganti M
    J Nucl Med; 2021 Oct; 62(10):1372-1379. PubMed ID: 33712534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response assessment of colorectal liver metastases with contrast enhanced CT/18F-FDG PET.
    García Vicente AM; Domínguez Ferreras E; Sánchez Pérez V; Poblete García VM; Villa Guzmán JC; Jiménez Aragón F; Pineda Pineda MD; Molino Trinidad C; Soriano Castrejón Á
    Eur J Radiol; 2013 Jun; 82(6):e255-61. PubMed ID: 23414715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PET/MR imaging in the detection and characterization of pulmonary lesions: technical and diagnostic evaluation in comparison to PET/CT.
    Rauscher I; Eiber M; Fürst S; Souvatzoglou M; Nekolla SG; Ziegler SI; Rummeny EJ; Schwaiger M; Beer AJ
    J Nucl Med; 2014 May; 55(5):724-9. PubMed ID: 24652827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-Time US-
    Mauri G; Gennaro N; De Beni S; Ierace T; Goldberg SN; Rodari M; Solbiati LA
    Cardiovasc Intervent Radiol; 2019 Jan; 42(1):60-68. PubMed ID: 30288593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrated FDG-PET/CT compared with intravenous contrast-enhanced CT for evaluation of metastatic regional lymph nodes in patients with resectable early stage esophageal cancer.
    Okada M; Murakami T; Kumano S; Kuwabara M; Shimono T; Hosono M; Shiozaki H
    Ann Nucl Med; 2009 Jan; 23(1):73-80. PubMed ID: 19205841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variation in radiotherapy target volume definition, dose to organs at risk and clinical target volumes using anatomic (computed tomography) versus combined anatomic and molecular imaging (positron emission tomography/computed tomography): intensity-modulated radiotherapy delivered using a tomotherapy Hi Art machine: final results of the VortigERN study.
    Chatterjee S; Frew J; Mott J; McCallum H; Stevenson P; Maxwell R; Wilsdon J; Kelly CG
    Clin Oncol (R Coll Radiol); 2012 Dec; 24(10):e173-9. PubMed ID: 23079100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.